Clinical Trials

The James Cancer Center Columbus, OH

open for enrollment

Ph III Pembrolizumab +Ipilimumab vs Pembrolizumab +Placebo in Previously Untreated, Stage IV, Metast

Protocol: OSU-17245

Full Title

A Phase III, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors are PD-L1 Positive (TPS ≥ 50%) (KEYNOTE-598)

Lung Cancers